Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Jaap Wieling to the role of Chief Executive Officer (CEO).
Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research and development (TNO, DSM, PRA/ICON, Xendo, QPS and BiosanaPharma). He is a seasoned expert in building effective and efficient product and platform development businesses and serves on the board and advisory committee of various (bio)pharmaceutical companies and (biopharmaceutical) service industries. For many years he has been invited as university lecturer on pharmaceutical product development. He holds a BSc degree in chemistry, an MSc degree in pharmacology and a PhD degree in Mathematics and Natural Sciences from Groningen University, The Netherlands. Dr. Wieling’s appointment to the PureIMS leadership team strengthens the company’s objective to advance the development of its clinical-stage lead program Levodopa Cyclops™ and highlights the aspirations to broadly exploit the business objectives with the Cyclops™ technology platform.
Mr. Robert Polano, partner at Carduso Capital said: “We are proud that we have managed to interest Dr. Jaap Wieling in PureIMS and its proprietary Cyclops™ technology and we are confident that the Cyclops™ business will prosper on his extensive life science experience and know how.”
Commenting on his appointment Dr. Wieling added: “I am very pleased to serve this company as CEO in the next stage of its development. I see a bright future for PureIMS’ technology that has already shown huge advantages over existing (pulmonary) delivery technologies with its in-house and partnering product pipeline, and also see many openings for new co-development, with partnering companies, for new delivery products with marketed compounds as well as NCE’s and NBE’s.”
About PureIMS
PureIMS is a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops™. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers.
PureIMS’ lead candidate, Levodopa Cyclops™, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease. One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Some three other clinical programs – including Epinephrine Cyclops™ for impending (food) allergy induced anaphylaxis – are being explored in an early clinical stage.
PureIMS also supports pharma/biotech partners, applying the Cyclops™-based inhalation route for their drug of choice.
PureIMS has developed a proprietary dry powder inhaler (DPI) called Cyclops™. Cyclops™ is an easy-to-handle, pre-loaded, credit card sized and disposable DPI, developed for high dose inhalation powders and is particularly suitable in situations requiring acute intervention. It can be produced in a cost-effective way because of its simple yet sophisticated proprietary design. Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages over standard-of-care DPIs across key therapeutic areas. These attributes enable its hygienic and effective use on a worldwide scale.
For more information, press, investors and pharma only:
Jaap Wieling
+31(0)50 205 3325
jwieling@pureims.com
For more information on Company:
